Roche And Proximagen SIGN VAP-1 Inflammatory Deal
This article was originally published in Scrip
Roche and Proximagen Ltd., a wholly owned UK subsidiary of Upsher-Smith laboratories, Inc. have announced a worldwide agreement for the further development of PRX700, an oral small molecule inhibitor vascular adhesion protein 1 (VAP-1), which is currently in phase II clinical development.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.